Detalhe da pesquisa
1.
DNA Repair Pathway in Ovarian Cancer Patients Treated with HIPEC.
Int J Mol Sci
; 24(10)2023 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37240218
2.
Trends in peritoneal surface malignancies: evidence from a Czech nationwide population-based study.
World J Surg Oncol
; 17(1): 182, 2019 Nov 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31694646
3.
Current status of cytoreductive surgery (CRS) and intraperitoneal hyperthermic chemotherapy (HIPEC) in the multimodal treatment of peritoneal surface malignancies.
Cas Lek Cesk
; 157(8): 419-428, 2018 Dec 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-30754979
4.
The outcome in patients with BRAF-mutated metastatic melanoma treated with anti-programmed death receptor-1 monotherapy or targeted therapy in the real-world setting.
Cancer Med
; 13(5): e6982, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38491825
5.
Hyperprogression on anti-PD-1 treatment. Is subsequent therapy feasible? A case report and review of the literature.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
; 167(4): 376-384, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35703362
6.
Cost analysis of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and the risk factors for their increased cost in a public insurance health care system - Single centre study.
Eur J Surg Oncol
; 46(4 Pt A): 607-612, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31982207
7.
Evaluation and management of toxicity of cytoreductive surgery/hyperthermic intraperitoneal chemotherapy: the initial experience of a single centre study.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
; 164(3): 300-306, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31435073
8.
Peritoneal Carcinomatosis from Ovarian Cancer - Current Clinical Impact of Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy.
Klin Onkol
; 32(5): 349-352, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31610667
9.
Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of the literature.
World J Gastroenterol
; 23(35): 6420-6428, 2017 Sep 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29085191
10.
Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome.
Oncol Lett
; 14(5): 5980-5988, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-29113235
11.
SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival.
Sci Rep
; 7: 43812, 2017 03 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28272475
12.
Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer.
Cancer Chemother Pharmacol
; 78(6): 1101-1111, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27250969
13.
Role of solute carrier transporters in pancreatic cancer: a review.
Pharmacogenomics
; 15(8): 1133-45, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25084206